Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device (FLXFit)
Primary Purpose
Degenerative Disc Disease, Spondylolisthesis, Retrolisthesis
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
FLXfit™ TLIF Interbody Fusion Device
Sponsored by
About this trial
This is an interventional treatment trial for Degenerative Disc Disease focused on measuring Degenerative Disc Disease, Spondylolisthesis, Retrolisthesis
Eligibility Criteria
Inclusion Criteria:
- Adult (18-70 y/o)
- Male or Female
With the following conditions of the lumbar spine as confirmed by advanced imaging (CT or MRI), who is a candidate for primary spinal fusion procedure according to acceptable criteria for such medical conditions:
- Degenerative disc disease with up to Grade I spondylolisthesis
- Spondylolisthesis
- Failure of at least 6-months conservative treatment
- BMI < 40
- Patient to approve no pregnancy during the 24 months of study and no participation in other studies in parallel to this one
- Ability to read, understand, and sign informed consent
Exclusion Criteria:
- Infection, local to the operative site
- Signs of local inflammation
- Fever or leukocytosis
- Pregnancy
- Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)
- Prior surgical procedure (with the exception of decompression only procedure) at the index level(s) using the desired operative approach
- Prior fusion procedure at an adjacent level
- Any other condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors or congenital abnormalities, fracture local to the operating site, elevation of segmentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count
- Neuromuscular disorder that would engender unacceptable risk of instability, implant fixation failure, or complications in postoperative care
- Active local infection in or near the operative region
- Active systemic infection and/or disease
- Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation
- Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, hypothyroidism)
- Systemic disease that requires the chronic administration of nonsteroidal anti-inflammatory or steroidal drugs
- Suspected or documented allergy or intolerance to implant's materials
- Symptomatic cardiac disease
- Patient unwilling to cooperate with postoperative instructions.
- Any case where the implant components selected for use would be too large or too small to achieve a successful result.
- Patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality.
- Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance.
- Prior fusion at the level to be treated.
- Back VAS < 4/10
Sites / Locations
- Rush University Medical Center; Department of Orthopedic Surgery
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
FLXfit™ TLIF Interbody Fusion Device
Arm Description
The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
Outcomes
Primary Outcome Measures
Safety/Adverse Events
All adverse events will be assessed by incidence and time to resolution of postoperative device-related complications and serious adverse events/incidence and time to reoperation/incidence and time to revision. All perioperative adverse events will be noted. Information will be obtained from the operative note regarding blood loos, length of surgery, procedural details and complications. Postoperative events including nausea, vomiting, wound complications, thromboembolic events will be assessed.
Secondary Outcome Measures
Disability
Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline. Mean change in score of the ODI from baseline to 24 months postoperatively
Change in Disability
Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline. Mean change in score of the ODI from baseline to 24 months postoperatively
Pain
Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the VAS from baseline to 24 months postoperatively
Change in Pain
Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the VAS from baseline to 24 months postoperatively
Health-Related Quality of Life Questionnaire
Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the SF-12 from baseline to 24 months postoperatively
Change in Health-Related Quality of Life Questionnaire
Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the SF-12 from baseline to 24 months postoperatively
Arthrodesis (Fusion)
CT based fusion assessment at 6 months, 12 months, and 24 months
Radiographic Analysis (Global Lumbar Lordosis)
Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing global lumbar lordosis (LL) at the level treated with the FLXfit device.
Radiographic Analysis (Segmental Lumbar Lordosis)
Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing segmental lumbar lordosis (LL) at the level treated with the FLXfit device.
Full Information
NCT ID
NCT02805985
First Posted
May 25, 2016
Last Updated
January 23, 2017
Sponsor
Expanding Orthopedics Ltd.
Collaborators
Rush University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02805985
Brief Title
Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device
Acronym
FLXFit
Official Title
Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 2016 (undefined)
Primary Completion Date
June 2018 (Anticipated)
Study Completion Date
June 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Expanding Orthopedics Ltd.
Collaborators
Rush University Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is a post-market clinical follow-up study. A post-market, prospective clinical trial will be conducted. The data collected from this study will serve the purpose of confirming safety and performance of the FLXfit™ implant.
Detailed Description
As detailed by Expanding Orthopedics Inc., the FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
The FLXfit™ is a unique titanium cage which articulates laterally as well as expands in height. This enables larger footprint support as well as restoration of disc height and lordotic angle correction. A bullet-nose design facilitates self-distraction and ease of insertion. The open architecture of the device allows it to be packed with autogenous bone graft.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Disc Disease, Spondylolisthesis, Retrolisthesis
Keywords
Degenerative Disc Disease, Spondylolisthesis, Retrolisthesis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
FLXfit™ TLIF Interbody Fusion Device
Arm Type
Experimental
Arm Description
The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
Intervention Type
Device
Intervention Name(s)
FLXfit™ TLIF Interbody Fusion Device
Intervention Description
The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
Primary Outcome Measure Information:
Title
Safety/Adverse Events
Description
All adverse events will be assessed by incidence and time to resolution of postoperative device-related complications and serious adverse events/incidence and time to reoperation/incidence and time to revision. All perioperative adverse events will be noted. Information will be obtained from the operative note regarding blood loos, length of surgery, procedural details and complications. Postoperative events including nausea, vomiting, wound complications, thromboembolic events will be assessed.
Time Frame
Up to 24 months
Secondary Outcome Measure Information:
Title
Disability
Description
Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline. Mean change in score of the ODI from baseline to 24 months postoperatively
Time Frame
24 months
Title
Change in Disability
Description
Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline. Mean change in score of the ODI from baseline to 24 months postoperatively
Time Frame
Up to 24 months
Title
Pain
Description
Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the VAS from baseline to 24 months postoperatively
Time Frame
24 months
Title
Change in Pain
Description
Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the VAS from baseline to 24 months postoperatively
Time Frame
Up to 24 months
Title
Health-Related Quality of Life Questionnaire
Description
Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the SF-12 from baseline to 24 months postoperatively
Time Frame
24 months
Title
Change in Health-Related Quality of Life Questionnaire
Description
Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the SF-12 from baseline to 24 months postoperatively
Time Frame
Up to 24 months
Title
Arthrodesis (Fusion)
Description
CT based fusion assessment at 6 months, 12 months, and 24 months
Time Frame
6 months, 12 months, 24 months
Title
Radiographic Analysis (Global Lumbar Lordosis)
Description
Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing global lumbar lordosis (LL) at the level treated with the FLXfit device.
Time Frame
Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits
Title
Radiographic Analysis (Segmental Lumbar Lordosis)
Description
Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing segmental lumbar lordosis (LL) at the level treated with the FLXfit device.
Time Frame
Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult (18-70 y/o)
Male or Female
With the following conditions of the lumbar spine as confirmed by advanced imaging (CT or MRI), who is a candidate for primary spinal fusion procedure according to acceptable criteria for such medical conditions:
Degenerative disc disease with up to Grade I spondylolisthesis
Spondylolisthesis
Failure of at least 6-months conservative treatment
BMI < 40
Patient to approve no pregnancy during the 24 months of study and no participation in other studies in parallel to this one
Ability to read, understand, and sign informed consent
Exclusion Criteria:
Infection, local to the operative site
Signs of local inflammation
Fever or leukocytosis
Pregnancy
Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)
Prior surgical procedure (with the exception of decompression only procedure) at the index level(s) using the desired operative approach
Prior fusion procedure at an adjacent level
Any other condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors or congenital abnormalities, fracture local to the operating site, elevation of segmentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count
Neuromuscular disorder that would engender unacceptable risk of instability, implant fixation failure, or complications in postoperative care
Active local infection in or near the operative region
Active systemic infection and/or disease
Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation
Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, hypothyroidism)
Systemic disease that requires the chronic administration of nonsteroidal anti-inflammatory or steroidal drugs
Suspected or documented allergy or intolerance to implant's materials
Symptomatic cardiac disease
Patient unwilling to cooperate with postoperative instructions.
Any case where the implant components selected for use would be too large or too small to achieve a successful result.
Patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality.
Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance.
Prior fusion at the level to be treated.
Back VAS < 4/10
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kern Singh, MD
Phone
312-432-2373
Email
kern.singh@rushortho.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dustin H Massel, BS
Organizational Affiliation
Rush University Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Benjamin C Mayo, BA
Organizational Affiliation
Rush University Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Fady Hijji, BS
Organizational Affiliation
Rush University Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Kern Singh, MD
Organizational Affiliation
Rush University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rush University Medical Center; Department of Orthopedic Surgery
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kern Singh, MD
Phone
312-432-2373
Email
kern.singh@rushortho.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device
We'll reach out to this number within 24 hrs